Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study

被引：0
|
作者：
Fang, Y. [1 ]
Pan, H. [1 ]
Shou, J. [2 ]
Hong, W. [3 ]
Yang, X. [4 ]
Zhu, D. [5 ]
Zhou, Y. [6 ]
Lan, F. [7 ]
Rao, C. [8 ]
Chen, J. [9 ]
机构：
[1] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Med Oncol, Hangzhou, Peoples R China
[2] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Peoples R China
[3] Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China
[4] First Hosp Jiaxing, Jiaxing, Peoples R China
[5] Jinhua Municipal Cent Hosp, Jinhua, Zhejiang, Peoples R China
[6] Cent Hosp Lishui City, Lishui, Peoples R China
[7] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[8] Univ Chinese Acad Sci, Hwa Mei Hosp, Ningbo, Peoples R China
[9] Ningbo Univ, Affiliated Peoples Hosp, Ningbo, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Anlotinib; NSCLC; anti-angiogenesis;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P86.22
引用
收藏
页码：S682 / S682
页数：1
相关论文
共 50 条
  • [41] Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer
    Novello, Silvia
    Falcone, Alfredo
    Crino, Lucio
    Rinaldi, Massimo
    Nardi, Mario
    De Marinis, Filippo
    Tonato, Maurizio
    Tibaldi, Carmelo
    Tinazzi, Angelo
    Russo, Francesca
    Grassivaro, Nicoletta
    Scagliotti, Giorgio Vittorio
    LUNG CANCER, 2009, 66 (03) : 327 - 332
  • [42] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    Feliu, J.
    Martin, G.
    Castro, J.
    Sundlov, A.
    Rodriguez-Jaraiz, A.
    Casado, E.
    Lomas, M.
    Madronal, C.
    Galan, A.
    Belda, C.
    Gonzalez-Baron, M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 527 - 531
  • [43] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    J. Feliu
    G. Martín
    J. Castro
    A. Sundlov
    A. Rodriguez-Jaráiz
    E. Casado
    M. Lomas
    C. Madroñal
    A. Galán
    C. Belda
    M. Gonzalez-Barón
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 527 - 531
  • [44] A phase Ib/II study of second-line cadonilimab, anlotinib and docetaxel in patients with checkpoint inhibitor (CPI)experienced advanced non-small cell lung cancer
    Han, B.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1646 - S1646
  • [45] A PHASE II STUDY OF DOCETAXEL MONOTHERAPY IN SECOND-LINE TREATMENT IN PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Reza, M. S.
    Hai, M. A.
    Chowdhury, Q.
    ANNALS OF ONCOLOGY, 2008, 19 : 119 - 120
  • [46] A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer
    Govindan, R
    Lim, WT
    Arquette, MA
    Goodner, SA
    Fears, CL
    Mortimer, JE
    Fracasso, PM
    ONCOLOGY REPORTS, 2006, 15 (01) : 123 - 127
  • [47] Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: Phase II trial
    Serke, M
    Schoenfeld, N
    Loddenkemper, R
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1211 - 1216
  • [48] Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: A phase III randomized trial
    Georgoulias, V.
    Ardavanis, A.
    Tsiafaki, X.
    Agelidou, A.
    Syrigos, K.
    Polyzos, A.
    Kakolyris, S.
    Kouroussis, Ch
    Androulakis, N.
    Chatzidaki, D.
    ANNALS OF ONCOLOGY, 2004, 15 : 169 - 169
  • [49] Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study
    Valerio, MR
    Russo, A
    Latteri, MA
    Modica, G
    Gulotta, G
    Armata, MG
    Bajardi, E
    Cicero, G
    Pantuso, G
    Grassi, N
    Agosta, G
    Gebbia, N
    LUNG CANCER, 2001, 34 : S31 - S35
  • [50] Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial
    Radhakrishnan, A.
    Bitran, J. D.
    Milton, D. T.
    Tolzien, K.
    Hallmeyer, S.
    Nabhan, C.
    JOURNAL OF CHEMOTHERAPY, 2009, 21 (04) : 439 - 444
12345